查看文章

Aims

The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial showed that rivaroxaban plus aspirin reduced major adverse cardiovascular events (MACE) in patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD). We explored whether the CHA 2 DS 2-VASc (congestive heart failure, hypertension, age≥ 75 years, diabetes, stroke/transient ischemic attack/thromboembolism, vascular disease, age 65-75 years, and sex category) and CHADS 2 scores can identify vascular patients at highest risk of recurrent events who may derive greatest benefits of treatment.

Methods

The predictive accuracies of the CHA 2 DS 2-VASc and CHADS 2 scores for the primary outcome, MACE, were assessed in COMPASS patients. Kaplan-Meier estimates of cumulative risk were used to compare the effects of rivaroxaban plus aspirin with aspirin alone according to …